natgillin/translations-raw huggingface dataset:
These salts (or esters, and/or amides) may be, for example, C1-8 alkyl, C3-8 cycloalkyl, aryl, C2-10 heteroaryl, or C2-10 non-aromatic heterocyclic salts (or esters, and/or amides). 
Te soli (ili esteri, i/ili amidi) mogu biti na primjer, C;.g alkilne, C3.g cikloalkilne, arilne, C2.19 heteroarilne, ili C2.19 nearomatske heterocikličke soli (ili estere, i/ili amide).
A method for monitoring a physiological signal of a user comprising receiving, collecting, storing, processing and/or transmitting one or more parameters indicative of at least one physiological signal of a user originating from at least one sensor as defined in any of embodiments 20-40 incorporated in a garment; and evaluating said physiological signal along the time. 
Postupak za praćenje fiziološkog signala korisnika sadrži primanje, skupljanje, skladištenje, obradu i / ili prijenos jednog ili više parametara indikativnih za barem jedan fiziološki signal korisnika podrijetlom iz najmanje jednog senzora (1) kako je definirano u bilo kojem od patentnih zahtjeva 8 -11 inkorporiranog u odjeću; i procjenjivanje navedenog fiziološkog signala tijekom vremena.
The container according to claim 1, wherein the fluid-collecting lip is a separate ring-formed element welded to the wall of the container. The container according to claim 6, wherein the separate ring-formed element forming the fluid-collecting lip includes downwardly-protruding reinforcing ribs. 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time što je rub za skupljanje tekućine (7) napravljen kao posebni element u obliku prstena zavaren za cilindričnu stijenku (2) spremnika (1).
A composition for use according to any one of claims 1, 2 or 5 or claims dependent thereon, further including an improvement in a communication domain in the human. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1, 2 ili 5, ili patentnih zahtjeva koji o njima ovise, naznačen time što dodatno uključuje poboljšavanje komunikacijskih vještina kod osobe.
FR-A 2 134 698 relates to O-substituted mononitrate esters of 1,4:3,6-dianhydro-D-glucitol which possess a cardiovascular activity. 
FR-A 2 134 698 se odnosi na O-supstituirane mononitrat estere 1,4:3,6-dianhidro-D-glucitola koji imaju kardiovaskularno djelovanje.
Transforms from hexagonal to rhomhedral phase at 1310° C. with a volume expansion of 8%. 
Transformira se iz heksagonske faze u romboedrijsku pri 1310 "C s ekspanzijom volumena od 6%.
In another preferred embodiment, the variable regions of the 1st and the 2nd CH3-domain comprising polypeptide chains recognize different target epitopes, whereas the variable regions of the 3rd and the 4th CH3-domain comprising polypeptide chains recognize the same target epitopes. 
Postupak u skladu patentnim zahtjevom 7, naznačen time što varijabilne regije prvog i drugog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju različite ciljne epitope, pri čemu varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju iste ciljne epitope.
The internal coating is over the entire inner surface of the shell. The shell 14 has an inward curl 44, see Figure 3, formed on its lower edge, and this inward curl engages the outer surface 4 of the cup wall 22 above the lower end of the cup 12 at a distance corresponding approximately to the height of the cup bottom 24. 
Ljuska 14 ima zavijutak 44 prema unutarnjoj strani, vidi sliku 3, koji zavijutak je načinjen na donjem rubu i ovaj zavijutak prema unutarnjoj strani zahvaća vanjsku površinu 4 stijenke tijela čaše 29 iznad donjeg kraja čaše 12 na razmaku koji odgovara približno visini od dna 24 čaše.
An isolated cell that expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence, wherein the cell is from, or obtainable from, the mouse of any one of the preceding claims, and wherein the cell comprises a hVλ and a hJλ which are operably linked to a mouse Ck gene segment at an endogenous mouse k immunoglobulin light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained. 
Izolirana stanica koja izražava antitijelo koje sadrži teški lanac koji sadrži preuređenu humanu sekvencu Vh-Dh-Jh i mišju sekvencu CH i laki lanac koji sadrži preuređenu humanu sekvencu preuređenu humanu sekvencu Vλ-Jλ i mišju sekvencu Ck, naznačena time, što je stanica iz ili se može dobiti iz miša prema bilo kojem od prethodnih patentnih zahtjeva, i naznačena time, što stanica sadrži:
is an oxygen atom, A2 is a nitrogen atom, Q1 is a single bond, Q2 is an ethylene group, and R1a and R1b are independently a lower alkyl group; or 
je atom kisika, A2 je atom dušika, Q1 je jednostruka veza, Q2 je etilen skupina, i R1a i R1b su nezavisno niža alkilna skupina; ili
Surprisingly, however, when 42-O-(D-fructosylcarbonyl)rapamycin or 42-O-(L-fucitolylcarbonyl)rapamycin were administered orally the level of rapamycin in the blood rose gradually to reach a maximum concentration at approximately 3 hours before gradually decreasing over time (Figure 6). 
Iznenađujuće je, međutim, da kod oralne primjene 42-O-(D-fruktozilkarbonil)rapamicina ili 42-O-(L-fucitolilkarbonil)rapamicina razina rapamicina u krvi raste postupno da bi dosegla maksimalnu koncentraciju nakon približno 3 sata prije nego postupno počne opadati s vremenom (slika 6).
The peptide of claim 1, comprising at positions 1 and 2 a pair of amino acids selected from the group consisting of: 
Peptid u skladu s patentnim zahtjevom 1, naznačen time što na položajima 1 i 2 sadrži par aminokiselina koje se bira iz skupine koju čine:
a contiguous sequence of the human λ light chain locus that spans from Vλ3-12 to Vλ3-1; 
graničnu sekvencu lokusa humanog lakog lanca λkoja se proteže od hVλ3- 12 do hVλ3-1;
In the most preferred embodiment the M3 antagonist of the invention and the B2-agonist are both present in the same pharmaceutical composition and are administered by inhalation through a common delivery device. 
U najpoželjnijem utjelovljenju, M3 antagonist sukladno predmetnom izumu i f2-agonist se nalaze u istom farmaceutskom pripravku i primjenjuju se inhalacijom putem zajedničke naprave za isporuku.
Further studies with this B16 artificial metastasis model revealed that the SDS levels in the final product do not appear to impact efficacy. 
Daljnje studije s ovim B16 modelom umjetnih metastaza otkrile su da razine SDS u konačnom proizvodu se ne čine od velikog utjecaja.
BEST MODE FOR CARRYING OUT THE INVENTION With particular reference to FIG. 1, the beacon 1 comprises an insulating casing 3 for supporting an electronic circuit 4, and for housing electronic circuit 4 in airtight manner inside beacon 1 . 
Uz osobito pozivanje na Sliku 1, baliza 1 se sastoji od izolirajućeg kućišta 3 za oslanjanje elektronskog kruga 4 i za smještaj elektronskog kruga 4 unutar balize 1 na način koji je nepropusan za zrak.
The liposome injection according to claim 15, characterized in that the said injection comprises an osmotic pressure regulator, wherein the said osmotic pressure regulator is selected from the group consisting of glucose, sucrose, sorbitol, mannitol, sodium chloride, glycerine, histidine and its hydrochloride, glycine and its hydrochloride, lysine, serine, glutamic acid, arginine, valine and a mixture thereof: the ratio of the said osmotic pressure regulator added is 0 ∼ 5% (w / v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija sadrži regulator osmotskog tlaka, pri čemu se taj regulator osmotskog tlaka izabire iz skupine koja obuhvaća glukozu, saharozu, sorbitol, manitol, natrijev klorid, glicerin, histidin i njegov hidroklorid, glicin i njegov hidroklorid, lizin, serin, glutaminsku kiselinu, arginin, valin i njihove smjese; omjer tog dodanog regulatora osmotskog tlaka je 0 ~ 5% (tež/vol), i minimum nije 0%.
A method of treating dementia associated with Parkinson's disease as adjunctive therapy to treatment with an acetylcholinesterase inhibitor comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment, wherein the effective daily dose administered to the patient is between about 30 and about 60 mg. 
dnevne doze N-(2-(6-fluoro-1H-indol-3-iljetil)-3-(2,2,3,3- tetrafluoropropoksi)benzilamina ili njegove farmaceutski prihvatljive soli pacijentu koji je u potrebi takvog liječenja, pri čemu djelotvorna dnevna doza primijenjena na pacijentu iznosi između 30 1 60 mg.
The process of any of claims 1 to 2, wherein the first conversion step is conducted for a first conversion time which is less than a value selected from the group consisting of 30 hours, 20 hours, 15 hours, and 10 hours. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se prvi korak pretvorbe provodi u vremenu prve pretvorbe koje je manje od 30 sati.
The method according to claim 1, wherein the oxidizing agents comprise halogen based compounds; permanganate salts; peroxides; ozone; sodium persulfate; potassium persulfate; oxidants produced by electrolytic methods, or a combination thereof. 
Postupak za obradu vode uz nizak trošak, prema bilo kojem od zahtjeva 1 do 6, naznačen time što oksidirajuća sredstva sadrže spojeve na bazi halogena; soli permanganata; perokside; ozon; natrijev persulfat; kalijev persulfat; oksidanse proizvedene elektrolitičkim postupcima, njihovu kombinaciju.
Usually, the composition will be applied repeatedly over a period of several weeks or months, depending on the ungual status. 
Obično se pripravak može primjenjivati više puta tijekom perioda od nekoliko tjedana ili mjeseci, ovisno o ungualnom statusu.
or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak naznačen time što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 12 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
One embodiment of the present invention pertains to compound of Formula (I) wherein X is NH, R1 is H or hydroxy; R2 is H or absent; is a single bond when R2 is H, or is a double bond when R2 is absent; and Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy and C3-5 cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
Jedan oblik prikazanog izuma se odnosi na spojeve Formule (I) gdje X je NH, R, je Hili hidroksi; R, je H ili je odsutan; je jednostruka veza kada je R, vodik ili je dvostruka veza kada je R» odsutan; Prsten A je 5-člani karbociklički prsten ili 5-člani heterociklički prsten po izboru supstituiran sa 1 do 4 supstituenda izabrana iz skupine koju čine halogen, C14 alkil, C,4 alkoksi i C3.5 cikloalkil; ili na njihove farmaceutski prihvatljive soli, solvate ili hidrate.
in the presence of lithium aluminum hydride in tetrahydrofuran at a temperature ranging from 0° C. to 15° C. to its corresponding alcohol (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol (2) 
= = ON u prisutnosti litijevog aluminijevog hidrida u tetrahidrofuranu kod temperature u rasponu od 0*C do 15*C u njegov odgovarajući alkohol (52,82,112,147,177)-ikoza-5,8,11,14,17-pentaen-1-ol (2) m
The composition of claim 4, wherein said copper compound is a copper salt and the copper salt is selected from the group consisting of copper carbonate, copper nitrate, copper sulfate, copper chloride, and combinations thereof. 
Sastav prema zahtjevu 3, naznačen time da je sol bakra odabrana iz skupine koja se sastoji iz bakar-karbonata, bakar-nitrata, bakar-sulfata, bakar-klorida i njihovih kombinacija.
A method according to any one of claims 1 - 7, wherein the Enteroviral particles are of an Enterovirus selected from the group consisting of polioviruses, Coxsackie A viruses, Coxsackie B viruses, Echoviruses, Rhinoviruses and Enteroviruses 68, 69, 70, 71 and 73 . 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 7, naznačen time što su enterovirusne čestice iz roda Enterovirus odabrane iz grupe koja se sastoji od poliovirusa, Coxsackie A virusa, Coxsackie B virusa, echovirusa, rinovirusa i enterovirusa 68, 69, 70, 71173.
removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VIII wherein A- is an anion; and 
(vi) uklanjanje zaštitne skupine sa soli koja ima formulu VII u prisutnosti otapala da bi se formirala sol koja ima formulu VIII (viti) gdje A- je anion; te
An oil dispersion according to any one of the previous claims, in which the content of the inorganic acid or the carboxylic acid is from 0.2 to 2 % by weight. 
HR P20140712 T1 Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da je udio anorganske kiseline ili karboksilne kiseline od 0.2 do 2 % težinski.
the variable light chain sequence of SEQ ID NO: 92 and variable heavy chain sequence of SEQ ID NO: 106; 
(h) varijabilno područje slabog lanca od sekvence SEQ ID NO: 92, 1 varijabilno područje jakog lanca od sekvence SEQ ID NO: 106;
The pharmaceutical composition according to claim 2, wherein the second peptide is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 20. 
HR P20190202 T1 HR P20190202 T1 PATENTNI ZAHTJEVI 1. = Peptid koji se sastoji od sekvence aminokiselina prema SEQ ID br. 10.
The composition of claim 1, wherein the solid herbicidal composition is a powder. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je čvrsti herbicidni pripravak prah ili granule.
The process according to claim 1, wherein the microbial content of the treated tobacco material is lower than the microbial content of the untreated tobacco material, and/or wherein the tobacco material at the end of the process is further processed for incorporation into a smoking article. The process according to claim 1, wherein the tobacco material at the end of the process is suitable for incorporation into a smoking article. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se duhanski materijal na kraju postupka dodatno obrađuje radi uključivanja u pušački artikl, ili što je duhanski materijal na kraju postupka pogodan za uključivanje u pušački artikl.
A composition, vaccine and/or antigen presenting cell as claimed in claim 10, for use in a method as defined in claim 10, wherein interleukin-2 (IL-2), interferon gamma (IFNY) and/or tumour necrosis factor alpha (TNFa) secretion is reduced and/or interleukin-10 (IL-10) secretion is increased in the method. 
Pripravak, cjepivo i/ili stanica koja ispoljava antigen prema zahtjevu 10, za uporabu u postupku kao što je definirano u zahtjevu 10, naznačen time da je u postupku smanjeno izlučivanje interleukina-2 (IL-2), interferona gama (IFNY) i/ili čimbenika tumorske nekroze alfa (TNFa) i/ili je povećano izlučivanje interleukina-10 (IL-10).
Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation. 
Upotreba izoliranog Sp35 antitijela ili antigen vezujućeg fragmenta istog u skladu sa zahtjevom 1 ili 2 za proizvodnju medikamenta za liječenje multiple skleroze.
The method for producing the crystal according to claim 36 or claim 37, wherein the solvent is selected from the group consisting of ethers, ketones, esters, alcohols, water, and a mixture solvent thereof. 
Postupak prema zahtjevu 22 ili 23, naznačen time što je otapalo je odabrano iz skupine koja se sastoji od etera, ketona, estera, alkohola, vode i njihove smjese otapala.
Hal represents fluoro or chloro, and and R2 represent, independently from one another, hydrogen or have one of the meanings of Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in a polar non-nucleophilic solvent at a temperature of minus 10°C to 50°C and in the presence of a suitable crown ether, to give the compound of formula (I). 
R! i R", međusobno neovisno, predstavljaju vodik ili jedno od značenja Hal; naznačen time što u navedenom postupku spoj formule (II) se prevodi u odgovarajući ester alkil-, fluoralkil- ili arilsulfonske kiseline, koji zatim reagira s nitritom alkalnog metala, u prisutnosti pogodnog krunastog etera, u polarnom nenukleofilnom otapalu, na temperaturi od -10 *C do 50 "€, kako bi se dobilo spoj formule (D).
A device as claimed in claim 1, characterised in that the means (14) for moving the slide (10) and the means (28) for moving the milling cutter (22) consist of pneumatic cylinders. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što sredstvo (14) za gibanje kliznika (10) 1 sredstvo (28) za gibanje glodala (22) se sastoji od pneumatskih cilindara.
The compound of claim 8, wherein R3 is methylamino, ethylamino, isopropylamino, tert-butylamino or cyclohexylamino. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što je R3 metilamino, etilamino, izopropilamino, tert-butilamino ili cikloheksilamino.
The terminal apparatus according to claim 1, wherein the remaining bit(s) are MSBs (Most Significant Bits) of the resource allocation information and the defined value is zero. 
Uređaj za prijenos prema zahtjevu 1 ili 2, naznačen time da su preostali bi(ovi) MSB-ovi, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
A is a poly (diethylene glycol)adipate having a theoretical molecular weight of from 500 to 3,500 Daltons; 
[image] pri čemu A je poliester koji ima teorijsku molekulsku masu od 500 do 3500 Daltona;
The compound as recited in any one or more of claims 1 to 5, wherein n is 3 and said compound contains a Y-phosphorothioate group; or wherein n is 4 and said compound contains a δ-phosphorothioate group; and wherein said compound is not hydrolyzed by DcpS under physiological conditions, and said compound inhibits cap-dependent translation. 
Tvar kako je nabrojena u jednom ili više od patentnih zahtjeva 1 do 5, pri čemu je n 3 i navedena tvar sadrži Y-fosfortioatnu grupu, ili pri čemu je n 4 i navedena tvar sadrži B- fosfortioatnu grupu; i pri čemu navedena tvar nije hidrolizirana s Dcp2 pod fiziološkim uvjetima, i navedena tvar inhibira cap-ovisnu translaciju.
A crystalline Form II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at one or both of 21.16 and 21.38 ± 0.20 degrees when measured against an internal silicon standard and characterized by an x-ray powder diffraction pattern further having at least four peaks, six peaks, eight peaks or all peaks expressed as 2θ at 4.48, 9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 and 25.00 ± 0.20 degrees when measured against an internal silicon standard. 
Kristalni oblik II (R)-7-kloro-N-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidroklorida - monohidrata, karakteriziran praškastim uzorkom raspršenja x-zraka koji ima pikove izražene kao 2 21.38 + 0.20 stupnjeva mjereno prema internom standardu silicija i karakteriziran praškastim uzorkom raspršenja x-zraka koji nadalje ima najmanje četiri pika, šest pikova, osam pikova ili sve pikove izražene kao 2 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 1 25.00 + 0.20 stupnjeva mjereno prema internom standardu silicija.
contacting said microorganism with a composition as set out in any one of claims 1 to 10. 
kontaktiranje tog mikroorganizma sa sastojkom temeljem bilo kojeg od zahtjeva 1 do 43.
at least one reducing monosaccharide at a final concentration from about 1% to about 5% w/v or about 1.5% to about 5% w/v or about 1.5% to about 4% w/v or about 2.5% to about 3% w/v or about 0.1% to about 0.3% w/v or 
najmanje jedan redukcijski monosaharid u konačnoj koncentraciji od oko 1% do oko 5% tež./vol. ili oko 1.5% do oko 5% tež./vol. ili oko 1.5% do oko 4% tež./vol. ili oko 2.5% do oko 3% tež./vol. ili oko 0.1% do oko 0.3% tež./vol. ili
is hydrogen or C1-6alkyl; is hydrogen or C1-6alkyl; or R12 and R13 taken together with the nitrogen atom to which they are substituted form imidazolyl. A compound according to claim 1 wherein R5 is C2-6alkenyl, 
R'? je vodik ili C,ealkil; R3 je vodik ili C,.galkil; ili R!? i R'? uzeti zajedno sa atomom dušika na koji su supstituirani formiraju imidazolil, Spoj prema bilo kojem od zahtjeva 1 do 5 naznačen time da R? je Cogalkenil, C> galkinil supstituiran sa Het, Ar, Het;
-X- is -L1-CH2CH3-, wherein L1 is an IgG1 hinge region, optionally mutated by substituting the first cysteine and wherein -CH2CH3- is the CH2CH3 region of an IgG1 Fc domain, optionally mutated to eliminate FcYRI-III interaction while retaining FcRn interaction; 
X- je -L1-CH2CH3-, gdje je L1 područje zgloba IgG1, koje može biti mutirano zamjenom prvog cisteina i gdje je -CH2CH3- područje CH2CH3 domene Fc IgG1, koje može biti mutirano kako bi se eliminiralo međudjelovanje FcYRI-III, uz očuvano međudjelovanje FcRn;
Modular antibody according to 8, which contains a binding site specifically binding to Her2 and contains an amino acid sequence selected from the group consisting of SEQ. ID numbers as listed in Table 4 and 5. 
Modularno protutijelo prema zahtjevu 6, naznačeno time, da se spomenuto mjesto vezanja antigena specifično veže na Her2 1 sadrži aminokiselinsku sekvencu odabranu iz skupine koja se sastoji od SEQ ID brojeva popisanih u Tablici 4 1 Tablici 5, te koja je u sastavu čvora EF i/ili čvora AB i/ili čvora CD.
The composition according to claim 2, further comprising a mucolytic agent, a bronchodialator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator, or a nutritional agent. 
Pripravak prema zahtjevu 19, naznačen time da nadalje sadrži mukolitičko sredstvo, bronhodilatator, antibiotik, protuinfektivno sredstvo, protuupalno sredstvo, modulator CFTR, ili prehrambeno sredstvo.
oxidising the resulting compound of formula (I) to form a compound of formula (I′): 
(11) oksidacije rezultirajućeg spoja formule (I) da se dobije spoj formule (T):
A pharmaceutical composition comprising a therapeutically-effective amount of a single immunoglobulin variable domain antibody of any of claims 1-11 and a pharmaceutically acceptable carrier. 
Farmaceutska smjesa koja sadrži terapijski-efikasnu količinu antitijela sa jednim imunoglobulinskim varijabilnim domenom iz bilo kojeg od patentnih zahtjeva 1-11 1 farmaceutski prihvatljiv nosač.
A process for the manufacture of crystalline sucrose from sugar palm juice comprising the crystallisation process according to any one of claims 4 to 6, wherein the solution of sucrose in the mixture of water and alcohol in the crystallisation vessel is provided (step a) by diluting sugar palm juice with the alcohol or with water and the alcohol and supplying the diluted juice to the crystallisation vessel. 
Postupak proizvodnje kristala saharoze iz soka šećerne palme koji sadrži postupak kristalizacije sukladno bilo kojem od zahtjeva 4 do 6, pri čemu je otopina saharoze u mješavini vode i alkohola u posudi za kristalizaciju pružena (korak a) otapanjem soka šećerne palme s alkoholom ili vodom i alkoholom 1 unošenjem razrijeđenog soka u posudu za kristalizaciju.
The structural characterizations of such ecteinascidins are not given again explicitly herein because from the detailed description provided in such references and citations therein; any person of ordinary skill in this technology is capable of obtaining such information directly from the sources cited here and related sources. 
Strukturne karakterizacije takvih ekteinascidina ovdje nisu ponovo točno navedene jer iz detaljnog opisa koji je dan u tim radovima i citatima, svaka tehnički kvalificirana osoba može dobiti takvu informaciju izravno iz izvora citiranih ovdje i sličnih.
The composition for use according to claim 1, wherein the FSD is female sexual arousal disorder (FSAD). 
Pripravak za uporabu prema zahtjevu 1, naznačen time da FSD je poremećaj seksualnog uzbuđenja kod žena (FSAD).